Intravenous Administration of Human γ‐Globulin*

Barandun, S; Kistler, P.; Jeunet, F; Isliker, H

doi:10.1111/j.1423-0410.1962.tb03240.x

Cited by 350 publications

(55 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the preparation of IMIG and IVIG differs at the end of the fractionation procedure where ethanol is removed in dif ferent ways: in the Cohn method (IMIG) freeze-drying is usually used, whereas in IVIG production gel filtration or diafiltration may be used. In addition, aggregated immu noglobulin is removed from IVIG by production steps like pepsin or PEG treatment [8,9]. Products prepared using virus (SFV) and vesicular stomatitis virus (VSV) were chosen for model viruses due to the fact they are relatively easy to grow in high titres and to quantify, and their hand ling is possible using ordinary laboratory facilities.…”

Section: Introductionmentioning

confidence: 99%

Virus Inactivation during Intravenous Immunoglobulin Production

Hämäläinen¹,

Suomela²,

Ukkonen³

1992

Vox Sanguinis

View full text Add to dashboard Cite

Effects of time, temperature, pH and stabilizers (i.e. medium) on inactivation of lipid-enveloped model viruses, Semliki Forest and vesicular stomatitis viruses in the production process of intravenous immunoglobulin were investigated on a laboratory scale. The lowering of pH, the raising of temperature and the increasing of incubation time improved the inactivation effect. However, small changes in pH and stabilizer concentrations did not influence the results. Inactivation was not linear and a clear tailing off could be seen. Therefore, for complete virus inactivation incubation times longer than 20 h are necessary. Inactivation took place much more rapidly in intravenous immunoglobulin solution than in intramuscular immunoglobulin solution. Processing steps such as freeze-dying in the presence of ethanol or storage of intramuscular immunoglobulin in the liquid state at pH 7 only partially inactivated these viruses.

show abstract

Section: Introductionmentioning

confidence: 99%

Virus Inactivation during Intravenous Immunoglobulin Production

Hämäläinen¹,

Suomela²,

Ukkonen³

1992

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…The apparent causes for intolerance reac tions to y-globulin administration appear to be anti-complementary activity [1] or anti body formation against the preservatives added to commercial preparations [3,18]. It Anti-immunoglobulin antibodies of dif ferent classes may be observed with a high frequency following blood transfusions or y-globulin therapy.…”

mentioning

confidence: 99%

Human IgE Response to the Administration of Blood Components

Ropars¹,

Geay-Chicot²,

Cartron³

et al. 1979

Vox Sanguinis

View full text Add to dashboard Cite

43 adults from a renal dialysis unit staff have received regularly spaced γ-globulin administrations for hepatitis B prophylaxis. Several blood samples were collected over a prolonged period of time (160 days). Following γ-globulin administration, anti-immunoglobulin antibodies of the IgE class were detected in 80% of this population, a fortnight after the first injection using serum absorptions on polymerized γ-globulins or a specific inverse RAST method. The reactivity pattern of these IgE anti-immunoglobulin antibodies was similar to that observed for the anti-immunoglobulin antibodies with ‘limited specificity’ detected by passive hemagglutination, in that they reacted with only one of the immunoglobulins of the panel used for their detection. A decrease of the overall IgE levels was observed in 62% of the subjects for a prolonged period of time following γ-globulin administration. This suggests a feedback regulation mechanism for the reagin production in man, as it has already been observed in animals. A high incidence of anti-immunoglobulin antibodies of various classes was observed in this study. However, only a small number (4/43) of adverse reactions appeared following γ-globulin administration. For some of these subjects, the presence of specific IgE anti-immunoglobulin, detected by the inverse-RAST technique, suggests a possible role of such antibodies in some intolerance reactions to γ-globulin administration.

show abstract

“…However, antibody deficient patients proved particularly reactive to "standard" IgG. 18 During the isolation procedure IgG molecules are inevitably altered and tend to form aggregates that remained in the "standard" IgG preparations because the production process did not include polishing steps to get rid of the altered/aggregated IgG molecules. The particular reactivity of antibody deficient patients made it impossible to apply "standard" IgG preparations via the intravenous route.…”

Section: Nabs In Immunoglobulin Concentrates: Historical Aspect Of Thmentioning

confidence: 99%

Naturally Occurring Antibodies/Autoantibodies in Polyclonal Immunoglobulin Concentrates

Späth

Lutz

2012

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

It was a long way from the use of hyperimmune animal sera for the treatment of toxin-producing infections to the production of polyclonal, polyspecific human immunoglobulin preparations and the use of NAbs as therapeutic tools for autoimmune and inflammatory diseases. Some highlights of the development of knowledge in blood fractionation techniques, basic science and clinical wisdom are reviewed in this chapter. Proudly we mention the outstanding contribution of Swiss scientists and clinicians in the development of IVIG as clinical tool for some otherwise untreatable diseases or taking advantage of its low adverse event profile in long-term treatment of other chronic autoimmune and inflammatory diseases. This chapter summarizes some of the characteristics and the effects in humans of NAbs which are present in IgG concentrates. We call attention to the fact that the human data remain, at least in part, incomplete, among others because even with the most efficient large-scale techniques available not more than approximately 50% of the total IgG in plasma can be fractionated into an immunoglobulin G concentrate.

show abstract

Intravenous Administration of Human γ‐Globulin*

Abstract: BerneThis work was supported by grants from the "Schweizeriscber Nationalfonds zur Forderung wissenschaftlicher Forschung", the "Kommission zur Forderung der EiweiBforschung an der Universitat Bern", and the "Sandoz-Stiftung zur Forderung der medizinisch-biologischen Forschung".

Cited by 350 publications

References 6 publications

Virus Inactivation during Intravenous Immunoglobulin Production

Virus Inactivation during Intravenous Immunoglobulin Production

Human IgE Response to the Administration of Blood Components

Naturally Occurring Antibodies/Autoantibodies in Polyclonal Immunoglobulin Concentrates

Contact Info

Product

Resources

About